We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Biovail Corp., faced with looming generic competition for its most profitable drug, will speed the development of other products, seek acquisitions and cancel a planned spinoff of a portfolio of older drugs.
Genzyme, the Cambridge, Mass., company that bought Bone Care International last year, is suing three former Bone Care executives, accusing them of stealing vitamin D-related discoveries that belong to the company and violating noncompete contracts.
GlaxoSmithKline Inc. has agreed to pay more than $41 million in restitution to end claims by more than 40 states that it inflated the prices of drugs used by cancer patients and others.
Sepracor Inc., a drug maker focused on respiratory and central nervous system disorders, said it will delay filing its latest quarterly report until a review of its stock option practices is completed.
Actavis Group hf., the international generic pharmaceuticals company, announces that it has submitted, on 9 August 2006, a request for the approval to publish a takeover bid for the acquisition of the Croatian pharmaceuticals company PLIVA d.d. Zagreb.
The FDA has sent a notice of violation letter to Eli Lilly over a patient brochure for the company's cancer medication, Alimta, prompting the drugmaker to withdraw the brochure from circulation.
The FDA moved to stop several pharmacies from manufacturing compounded inhalation drugs in the agency's latest attempt to curb a practice that it believes to be unsafe.